|
π¦
|
Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.
23 auth.
J. Korn,
M. Mayes,
M. Cerinic,
M. Rainisio,
J. Pope,
E. Hachulla,
Γ. Rich,
P. Carpentier,
J. Molitor,
J. Seibold,
...
V. Hsu,
L. Guillevin,
Sharmila Chatterjee,
H. Peter,
J. Coppock,
A. Herrick,
P. Merkel,
R. Simms,
C. Denton,
D. Furst,
N. Nguyen,
M. Gaitonde,
C. Black
|
9 |
2004 |
9
π¦
|
|
π¬
|
Structure and expression of cDNA and genes for human interferonβbetaβ2, a distinct species inducible by growthβstimulatory cytokines.
A. Zilberstein,
R. Ruggieri,
J. Korn,
M. Revel
|
8 |
1986 |
8
π¬
|
|
π
|
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192.
20 auth.
C. Denton,
P. Merkel,
D. Furst,
D. Khanna,
P. Emery,
V. Hsu,
N. Silliman,
J. Streisand,
J. Powell,
A. Γ
kesson,
...
J. Coppock,
F. Hoogen,
A. Herrick,
M. Mayes,
D. Veale,
J. Haas,
S. Ledbetter,
J. Korn,
C. Black,
J. Seibold
|
8 |
2007 |
8
π
|
|
π
|
Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.
19 auth.
P. Merkel,
K. Herlyn,
Richard W. Martin,
Jennifer J. Anderson,
M. Mayes,
P. Bell,
J. Korn,
R. Simms,
M. Csuka,
T. Medsger,
...
N. Rothfield,
M. Ellman,
D. Collier,
A. Weinstein,
D. Furst,
S. Jimenez,
B. White,
J. Seibold,
F. Wigley
|
8 |
2002 |
8
π
|
|
π¦
|
Mononuclear cell modulation of connective tissue function: suppression of fibroblast growth by stimulation of endogenous prostaglandin production.
J. Korn,
P. Halushka,
E. Leroy
|
8 |
1980 |
8
π¦
|
|
π
|
Recombinant Human Relaxin in the Treatment of Scleroderma
20 auth.
J. Seibold,
J. Korn,
R. Simms,
P. Clements,
L. Moreland,
Maureen D. Mayes,
Daniel Furst,
N. Rothfield,
V. Steen,
M. Weisman,
...
D. Collier,
Fredrick Wigley,
P. Merkel,
M. Csuka,
V. Hsu,
S. Rocco,
M. Erikson,
J. Hannigan,
W. S. Harkonen,
Martin E. Sanders
|
8 |
2000 |
8
π
|
|
π’
|
Role of apoptosis and transforming growth factor beta1 in fibroblast selection and activation in systemic sclerosis.
A. Jelaska,
J. Korn
|
7 |
2000 |
7
π’
|
|
π
|
Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.
18 auth.
D. Khanna,
D. Furst,
P. Clements,
G. Park,
R. Hays,
J. Yoon,
J. Korn,
P. Merkel,
N. Rothfield,
F. Wigley,
...
L. Moreland,
R. Silver,
V. Steen,
M. Weisman,
M. Mayes,
D. Collier,
T. Medsger,
J. Seibold
|
7 |
2005 |
7
π
|
|
π¬
|
Differential Regulation of Cyclooxygenases 1 and 2 by Interleukin-1Ξ², Tumor Necrosis Factor-Ξ±, and Transforming Growth Factor-Ξ²1 in Human Lung Fibroblasts
A. Diaz,
K. Chepenik,
J. Korn,
A. Reginato,
S. Jimenez
|
7 |
1998 |
7
π¬
|
|
π
|
Durometry for the assessment of skin disease in systemic sclerosis.
8 auth.
E. Kissin,
A. M. Schiller,
R. Gelbard,
Jennifer J. Anderson,
V. Falanga,
R. Simms,
...
J. Korn,
P. Merkel
|
7 |
2006 |
7
π
|
|
π
|
Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.
23 auth.
D. Khanna,
P. Clements,
D. Furst,
J. Korn,
M. Ellman,
N. Rothfield,
F. Wigley,
L. Moreland,
R. Silver,
Youn H. Kim,
...
V. Steen,
G. Firestein,
A. Kavanaugh,
M. Weisman,
M. Mayes,
D. Collier,
M. Csuka,
R. Simms,
P. Merkel,
T. Medsger,
M. Sanders,
P. Maranian,
J. Seibold
|
7 |
2009 |
7
π
|
